{"result": "(\"entity\"<|>DU<|>PERSON<|>First author of a study conducted in 2021 in China on the effects of topical minoxidil and compound glycyrrhizin>)\n##\n(\"entity\"<|>YANG<|>PERSON<|>First author of a study conducted in 2021 in China, researching the combined effects of topical minoxidil and varying doses of compound glycyrrhizin>)\n##\n(\"entity\"<|>LI<|>PERSON<|>First author of two studies, one conducted in 2020 and another in 2009 in China, focusing on topical minoxidil and compound glycyrrhizin treatment>)\n##\n(\"entity\"<|>WANG<|>PERSON<|>First author of a study conducted in 2016 in China, investigating the effects of topical minoxidil and compound glycyrrhizin on a specific condition>)\n##\n(\"entity\"<|>CHEN<|>PERSON<|>First author of a study conducted in 2015 in China, exploring the efficacy of topical minoxidil and compound glycyrrhizin>)\n##\n(\"entity\"<|>YUE<|>PERSON<|>First author of a study conducted in 2015 in China, examining the effects of 2% topical minoxidil and compound glycyrrhizin>)\n##\n(\"entity\"<|>FU<|>PERSON<|>First author of a study conducted in 2013 in China, researching the impact of topical minoxidil and compound glycyrrhizin on patients>)\n##\n(\"entity\"<|>CAO<|>PERSON<|>First author of a study conducted in 2012 in China, focusing on the treatment with topical minoxidil and compound glycyrrhizin>)\n##\n(\"entity\"<|>YU<|>PERSON<|>First author of a study conducted in 2012 in China, investigating the combined treatment effects of topical minoxidil and compound glycyrrhizin>)\n##\n(\"entity\"<|>WU<|>PERSON<|>First author of a study conducted in 2011 in China, studying the effects of topical minoxidil and compound glycyrrhizin on a specific patient group>)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4-turbo-preview", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: signifcant difference \nin the incidence of irritant contact dermatitis (RR = 0.51, 95% CI \n[0.25, 1.01], p = 0.05), gastrointestinal reactions (RR = 2.47, 95% CI \n[0.49, 12.55], p = 0.28), lower limb edema (RR = 2.60, 95% CI [0.61, \n11.06], p = 0.20), facial edema (RR = 2.33, 95% CI [0.61, 8.93], \np = 0.22), and localized itching (RR = 0.56, 95% CI [0.18, 1.75], \np = 0.32) between the two groups. Other adverse reactions included \ndizziness [ 16] and mild increase in blood pressure [ 23]. All of these \nadverse reactions in the two groups can be resolved sponta -\nneously and did not affect subsequent treatment ( Figure 9 ).\nSensitivity analysis\nThe sensitivity analyses were performed using the method of \nomitting individual studies one by one to evaluate the influence \non pooled results due to the heterogeneity of the meta-analyses \non the clinical efficacy, SALT score, serum TNF-α, TGF-β1, IL-12 and \nIFN-γ levels. The analyses indicated there were no significant influ -\nences on any outcome, suggesting that the sensitivity was low \nand the results were robust ( Figure 10 ).\nAssessment of publication bias\nThe funnel plot analysis of clinical effective rate showed asymme -\ntry, which indicated potential publication bias ( Figure 11 ).Table 1.  included studies characteristics.\nfirst a uthor \nYear countrySample \nsize (e/c ) m:fmean age or age range \n(e/c ) Disease course (e/c ) interventiontreatment \ncourse outcomes\nDu 2021 [ 25] china 60/60 71:49 45.71 ± 3.69/44.93 ± 3.72 6.69 ± 1.28m/6.38 ± 1.43m 5% topical minoxidil \ntwice a day + cg \n50 mg tiD3m①②③④⑤\nYang 2021 [ 26]china 45/44 57:32 33.15 ± 10.65/32.51 ± 9.87 8.54 ± 2.63m/8.61 ± 2.87m 5% topical minoxidil \ntwice a day + cg \n25–75mg tiD3m①④⑥⑦\nli 2020 [ 27] china 75/74 81:68 40.34 ± 10.28/39.18 ± 9.67 9.36 ± 4.17m/9.87 ± 4.03m 5% topical minoxidil \ntwice a day + cg \n50 mg tiD3m①②⑦\nWang 2016 [ 28]china 60/60 83:27 19–57/19–59 4–41m/3–39m 5% topical minoxidil \ntwice a day + cg \n50 mg tiD2m①⑦\nchen 2015 [ 29]china 55/55 60:50 44.5 ± 15.4/47.5 ± 16.7 6.5 ± 2.5m/6.2 ± 2.0m 5% topical minoxidil \ntwice a day + cg \n75 mg tiD3m①②③④⑤⑦\nYue 2015 [ 30] china 55/55 62:48 nr nr 2% topical minoxidil \ntwice a day + cg \n25–50mg tiD3m①⑦\nfu 2013 [ 31] china 60/60 56:64 41.5 ± 13.0/41.9 ± 13.5 5.2 ± 2.0m/5.5 ± 2.6m 5% topical minoxidil \ntwice a day + cg \n50 mg tiD3m①②⑥⑦\ncao 2012 [ 32] china 42/44 52:34 12–66/15–64 25d–13y/21d–11.8y 5% topical minoxidil \ntwice a day + cg \n75 mg tiD3m①②\nYu 2012 [ 33] china 53/51 59:45 nr nr 5% topical minoxidil \ntwice a day + cg \n75 mg tiD3m①⑦\nWu 2011 [ 34] china 50/50 52:48 nr nr 5% topical minoxidil \ntwice a day + cg \n25–75mg tiD2m①⑦\nli 2009 [ 27] china 48/33 50:31 16–60/17–58 6d–1y/7d–1y 5% topical minoxidil \ntwice a day + cg \n50 mg tiD3m①⑦\nabbreviations: cg: compound glycyrrhizin; m: male; f : female; e: experimental group; c\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>IRRITANT CONTACT DERMATITIS<|>EVENT<|>A skin condition mentioned in the study with a relative risk (RR) of 0.51, indicating its incidence in comparison between two groups>)\n##\n(\"entity\"<|>GASTROINTESTINAL REACTIONS<|>EVENT<|>Adverse reactions involving the digestive system with a RR of 2.47, as reported in the study>)\n##\n(\"entity\"<|>LOWER LIMB EDEMA<|>EVENT<|>Swelling of the lower limbs with a RR of 2.60, as identified in the study's findings>)\n##\n(\"entity\"<|>FACIAL EDEMA<|>EVENT<|>Swelling of the face with a RR of 2.33, as observed in the study>)\n##\n(\"entity\"<|>LOCALIZED ITCHING<|>EVENT<|>A condition of itching localized to certain areas with a RR of 0.56, as mentioned in the research>)\n##\n(\"entity\"<|>DIZZINESS<|>EVENT<|>An adverse reaction reported in the study without a specified RR but noted among the effects>)\n##\n(\"entity\"<|>BLOOD PRESSURE INCREASE<|>EVENT<|>A mild increase in blood pressure noted as an adverse reaction in the study>)\n##\n(\"entity\"<|>SENSITIVITY ANALYSIS<|>EVENT<|>A methodological approach used in the study to evaluate the influence of individual studies on the pooled results>)\n##\n(\"entity\"<|>PUBLICATION BIAS<|>EVENT<|>A potential bias in published research, indicated by asymmetry in the funnel plot analysis>)\n##\n(\"entity\"<|>CHINA<|>GEO<|>Country where the studies included in the meta-analysis were conducted>)\n##\n(\"entity\"<|>TOPICAL MINOXIDIL<|>ORGANIZATION<|>A treatment used in the studies for conditions possibly related to hair loss or skin conditions, applied twice a day>)\n##\n(\"entity\"<|>COMPOUND GLYCYRRHIZIN<|>ORGANIZATION<|>A compound used in conjunction with topical minoxidil in the studies, indicated for its potential therapeutic effects>)\n<|COMPLETE|>"}]}